Compare KWR & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | TMDX |
|---|---|---|
| Founded | 1918 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 1994 | 2019 |
| Metric | KWR | TMDX |
|---|---|---|
| Price | $151.15 | $73.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $167.00 | $148.22 |
| AVG Volume (30 Days) | 141.5K | ★ 969.8K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | ★ 1.13 | 0.20 |
| Revenue | ★ $1,888,634,000.00 | $605,494,000.00 |
| Revenue This Year | $5.16 | $24.25 |
| Revenue Next Year | $3.63 | $18.75 |
| P/E Ratio | ★ $131.70 | $355.65 |
| Revenue Growth | 2.66 | ★ 37.13 |
| 52 Week Low | $111.42 | $60.11 |
| 52 Week High | $183.01 | $156.00 |
| Indicator | KWR | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 47.33 |
| Support Level | $146.59 | $64.87 |
| Resistance Level | $155.88 | $79.60 |
| Average True Range (ATR) | 5.32 | 3.13 |
| MACD | -0.58 | 0.02 |
| Stochastic Oscillator | 63.41 | 34.57 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.